{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:26Z","timestamp":1756902146113,"version":"3.44.0"},"reference-count":38,"publisher":"The Pediatric Pharmacy Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4,1]]},"abstract":"<jats:p>OBJECTIVE: To evaluate the usefulness of extended-interval gentamicin dosing practiced in neonatal intensive care unit (NICU) and special care nursery (SCN) of a Malaysian hospital.<\/jats:p>\n               <jats:p>METHODS: Cross-sectional observational study with pharmacokinetic analysis of all patients aged \u226428 days who received gentamicin treatment in NICU\/SCN. Subjects received dosing according to a regimen modified from an Australian-based pediatric guideline. During a study period of 3 months, subjects were evaluated for gestational age, body weight, serum creatinine concentration, gentamicin dose\/interval, serum peak and trough concentrations, and pharmacokinetic parameters. Descriptive percentages were used to determine the overall dosing accuracy, while analysis of variance (ANOVA) was conducted to compare the accuracy rates among different gestational ages. Pharmacokinetic profile among different gestational age and body weight groups were compared by using ANOVA.<\/jats:p>\n               <jats:p>RESULTS: Of the 113 subjects included, 82.3% (n = 93) achieved therapeutic concentrations at the first drug-monitoring assessment. There was no significant difference found between the percentage of term neonates who achieved therapeutic concentrations and the premature group (87.1% vs. 74.4%), p = 0.085. A total of 112 subjects (99.1%) achieved desired therapeutic trough concentration of &amp;lt;2 mg\/L. Mean gentamicin peak concentration was 8.52 mg\/L (95% confidence interval [Cl], 8.13\u20138.90 mg\/L) and trough concentration was 0.54 mg\/L (95% CI, 0.48\u20130.60 mg\/L). Mean volume of distribution, half-life, and elimination rate were 0.65 L\/kg (95% CI, 0.62\u20130.68 L\/kg), 6.96 hours (95% CI, 6.52\u20137.40 hours), and 0.11 hour\u22121 (95% CI, 0.10\u20130.11 hour\u22121), respectively.<\/jats:p>\n               <jats:p>CONCLUSION: The larger percentage of subjects attaining therapeutic range with extended-interval gentamicin dosing suggests that this regimen is appropriate and can be safely used among Malaysian neonates.<\/jats:p>","DOI":"10.5863\/1551-6776-20.2.119","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T19:56:07Z","timestamp":1603828567000},"page":"119-127","source":"Crossref","is-referenced-by-count":5,"title":["Extended-Interval Gentamicin Dosing in Achieving Therapeutic Concentrations in Malaysian Neonates"],"prefix":"10.5863","volume":"20","author":[{"given":"Yee Shan","family":"Low","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sultanah Fatimah Specialist Hospital, Muar, Johor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sin Li","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sultanah Fatimah Specialist Hospital, Muar, Johor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeline SL","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Sultanah Fatimah Specialist Hospital, Muar, Johor"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"6","key":"2020102715523589500_i1551-6776-20-2-119-b1","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1542\/peds.2005-1707","article-title":"Reported medication use in the neonatal intensive care unit: data from a large national data set","volume":"117","author":"Clark","year":"2006","journal-title":"Pediatrics"},{"issue":"9","key":"2020102715523589500_i1551-6776-20-2-119-b2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/01.inf.0000178064.55193.1c","article-title":"Use of antimicrobial agents in United States neonatal and pediatric intensive care patients","volume":"24","author":"Grohskopf","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"2020102715523589500_i1551-6776-20-2-119-b3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jac\/49.1.13","article-title":"Newborns and gentamicin\u2014how much and how often?","volume":"49","author":"Chattopadhyay","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2020102715523589500_i1551-6776-20-2-119-b4","first-page":"CD005091","article-title":"One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates","volume":"1","author":"Rao","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2020102715523589500_i1551-6776-20-2-119-b5","first-page":"264","article-title":"Accuracy of empiric gentamicin dosing guidelines in neonates","volume":"15","author":"Hitron","year":"2010","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"2020102715523589500_i1551-6776-20-2-119-b6","first-page":"92","article-title":"Evaluation of 22 neonatal gentamicin dosage protocols using a Bayesian approach","volume":"4","author":"Lannigian","year":"2001","journal-title":"Paediatr Perinat Drug Ther"},{"issue":"4","key":"2020102715523589500_i1551-6776-20-2-119-b7","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/adc.2004.056317","article-title":"Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis","volume":"90","author":"Nestaas","year":"2005","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"2020102715523589500_i1551-6776-20-2-119-b8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/157339609787587582","article-title":"Peak and trough concentration of Gentamicin in the neonate: a review of the literature","volume":"5","author":"Pacifici","year":"2009","journal-title":"Curr Pediatr Rev"},{"issue":"12","key":"2020102715523589500_i1551-6776-20-2-119-b9","first-page":"2601","article-title":"Efficacy and safety of gentamicin by interval and intravenous dosage adjustment based on the gestational age in Thai neonates","volume":"90","author":"Tantiprabha","year":"2007","journal-title":"J Med Assoc Thai"},{"issue":"1","key":"2020102715523589500_i1551-6776-20-2-119-b10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4103\/0253-7613.91864","article-title":"Pharmacokinetic approach for optimizing gentamicin use in neonates during the first week of life","volume":"44","author":"Ali","year":"2012","journal-title":"Indian J Pharmacol"},{"key":"2020102715523589500_i1551-6776-20-2-119-b11","unstructured":"Shann\n              F.\n            \n          \n          Drug Doses. 15th ed.Melbourne, Australia: Collective P\/L; 2010:42."},{"issue":"5","key":"2020102715523589500_i1551-6776-20-2-119-b12","first-page":"640","article-title":"Simplified dosing of gentamicin for treatment of sepsis in Bangladeshi neonates","volume":"27","author":"Hossain","year":"2009","journal-title":"J Health Popul Nutr"},{"issue":"4","key":"2020102715523589500_i1551-6776-20-2-119-b13","first-page":"92","article-title":"Gentamicin in preterm neonates: an extended interval dosing schedule","volume":"13","author":"Veltkamp","year":"2007","journal-title":"Eur J Hosp Pharm"},{"issue":"6","key":"2020102715523589500_i1551-6776-20-2-119-b14","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/jac\/48.6.887","article-title":"An extended interval dosing method for gentamicin in neonates","volume":"48","author":"Stickland","year":"2001","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2020102715523589500_i1551-6776-20-2-119-b15","first-page":"163","article-title":"Extended-interval dosing of gentamicin for treatment of neonatal sepsis in developed and developing countries","volume":"26","author":"Darmstadt","year":"2008","journal-title":"J Health Popul Nutr"},{"key":"2020102715523589500_i1551-6776-20-2-119-b16","first-page":"13","article-title":"Differences between paediatric populations and adults","author":"World Health Organization","year":"2007","journal-title":"Promoting Safety of Medicines for Children"},{"key":"2020102715523589500_i1551-6776-20-2-119-b17","first-page":"642","article-title":"Gentamicin","author":"Taketomo","year":"2010","journal-title":"Pediatric Dosage Handbook"},{"issue":"7","key":"2020102715523589500_i1551-6776-20-2-119-b18","first-page":"934","article-title":"Once-daily gentamicin dosing of 4 mg\/kg\/dose in neonates","volume":"88","author":"Kiatchoosakun","year":"2005","journal-title":"J Med Assoc Thai"},{"issue":"1 Spec No","key":"2020102715523589500_i1551-6776-20-2-119-b19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/adc.67.1_Spec_No.57","article-title":"Pharmacokinetics and antibacterial activity of daily gentamicin","volume":"67","author":"Skopnik","year":"1992","journal-title":"Arch Dis Child"},{"issue":"6","key":"2020102715523589500_i1551-6776-20-2-119-b20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1440-1754.1998.00306.x","article-title":"Gentamicin dosage intervals in neonates: longer dosage intervalless toxicity","volume":"34","author":"Davies","year":"1998","journal-title":"J Paediatr Child Health"},{"issue":"8","key":"2020102715523589500_i1551-6776-20-2-119-b21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.jp.7210996","article-title":"Once daily gentamicin dosing for the preterm and term newborn: proposal for a simple regimen that achieves target level","volume":"23","author":"Hansen","year":"2003","journal-title":"J Perinatol"},{"issue":"6","key":"2020102715523589500_i1551-6776-20-2-119-b22","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1128\/AAC.35.6.1070","article-title":"Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration","volume":"35","author":"Beaubien","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2020102715523589500_i1551-6776-20-2-119-b23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2165\/00003088-197803030-00002","article-title":"Why monitor serum levels of gentamicin?","volume":"3","author":"Barza","year":"1978","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2020102715523589500_i1551-6776-20-2-119-b24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1592\/phco.23.5.585.32196","article-title":"A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates","volume":"23","author":"DiCenzo","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"11","key":"2020102715523589500_i1551-6776-20-2-119-b25","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1592\/phco.29.11.1297","article-title":"Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates","volume":"29","author":"Hoff","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"3","key":"2020102715523589500_i1551-6776-20-2-119-b26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00007691-199206000-00001","article-title":"Population pharmacokinetics of gentamicin in premature infants","volume":"14","author":"Izquierdo","year":"1992","journal-title":"Ther Drug Monit"},{"issue":"1","key":"2020102715523589500_i1551-6776-20-2-119-b27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/clinchem\/43.1.222","article-title":"Therapeutic drug monitoring principles in the neonate","volume":"43","author":"Koren","year":"1997","journal-title":"Clin Chem"},{"issue":"6","key":"2020102715523589500_i1551-6776-20-2-119-b28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2165\/00003495-200161060-00001","article-title":"Aminoglycoside adaptive resistance: importance for effective dosage regimens","volume":"61","author":"Barclay","year":"2001","journal-title":"Drugs."},{"issue":"3","key":"2020102715523589500_i1551-6776-20-2-119-b29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1542\/peds.103.3.594","article-title":"Once-versus twice-daily gentamicin dosing in neonates \u2265 34 weeks' gestation: cost-effectiveness analyses","volume":"103","author":"Thureen","year":"1999","journal-title":"Pediatrics"},{"issue":"1","key":"2020102715523589500_i1551-6776-20-2-119-b30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"issue":"5","key":"2020102715523589500_i1551-6776-20-2-119-b31","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/jac\/dkp073","article-title":"Eight years' experience of an extended-interval dosing protocol for gentamicin in neonates","volume":"63","author":"Begg","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2020102715523589500_i1551-6776-20-2-119-b32","first-page":"55","article-title":"Aminoglycoside antibiotics","author":"Bauer","year":"2005","journal-title":"Clinical Pharmacokinetics Handbook"},{"article-title":"Gentamicin\u2013ototoxicity in children","year":"2008","author":"Matthai","key":"2020102715523589500_i1551-6776-20-2-119-b33"},{"issue":"5","key":"2020102715523589500_i1551-6776-20-2-119-b34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/tropej\/fmn059","article-title":"Evidence behind the WHO guidelines: hospital care for children: what is the evidence of safety of gentamicin use in children?","volume":"54","author":"McGlone","year":"2008","journal-title":"J Trop Pediatr"},{"issue":"2","key":"2020102715523589500_i1551-6776-20-2-119-b35","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000324857","article-title":"Are gentamicin and\/or vancomycin associated with ototoxicity in the neonate: a retrospective audit","volume":"100","author":"Vella-Brincat","year":"2011","journal-title":"Neonatology"},{"issue":"6","key":"2020102715523589500_i1551-6776-20-2-119-b36","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/adc.2007.124214","article-title":"Hearing loss in children with very low birth weight: current review of epidemiology and pathophysiology","volume":"93","author":"Cristobal","year":"2007","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"4","key":"2020102715523589500_i1551-6776-20-2-119-b37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/sj.jp.7210704","article-title":"Comparison of once-daily versus twice-daily gentamicin dosing regimens in infants \u2265 2500g","volume":"22","author":"Agarwal","year":"2002","journal-title":"J Perinatol"},{"issue":"1","key":"2020102715523589500_i1551-6776-20-2-119-b38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1542\/peds.114.1.e111","article-title":"Extended-interval aminoglycoside administration for children: a meta-analysis","volume":"114","author":"Contopoulos-Ioannidis","year":"2004","journal-title":"Pediatrics"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/20\/2\/119\/1783442\/1551-6776-20_2_119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/20\/2\/119\/1783442\/1551-6776-20_2_119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:34:23Z","timestamp":1738780463000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/20\/2\/article-p119.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,1]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-20.2.119","relation":{},"ISSN":["1551-6776"],"issn-type":[{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2015,4,1]]}}}